Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

KYMR

Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1815442Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.04B
Net Income FY2025
$(0.31B)
EPS (Basic, as reported)
$-3.69
Net Margin FY2025
-794.0%
ROE FY2025
-19.7%
Total Equity
$1.58B
Shares Out
83M
Business description

Kymera Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 3 → 39 +53.3% CAGR
Fiscal yearFY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025
Revenue3347347794739
Cost of revenue———(47)(79)(47)(39)
Research & development(37)(62)(137)(164)(189)(240)(317)
General & administrative(8)(18)(36)(44)(55)(64)(68)
Total operating expenses(45)(80)(173)(208)(244)(309)(389)
Operating income(42)(46)(101)(161)(166)(262)(349)
Other income (expense), net1106193838
Pre-tax income——————(311)
Income tax expense0000——0
Net income(41)(46)(100)(155)(147)(224)(311)
EPS — basic—($3.15)($2.09)($2.87)($2.52)($2.98)($3.69)
EPS — diluted—($3.15)($2.09)($2.87)($2.52)($2.98)($3.69)
Shares outstanding — basic (M)—174854587584
Shares outstanding — diluted (M)—174854587584
  • ⚑ Weighted-average shares changed ×2.82 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.